JAK3 inhibitors have become a buzzword in pharmaceuticals, with significant implications for treating various diseases, including autoimmune disorders and cancers. JAK (Janus Kinase) inhibitors, ...
Please provide your email address to receive an email when new articles are posted on . The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work ...
WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback